Cargando…

Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers

BACKGROUND: This study aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers after voluntary vaccination with Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA-based vaccine. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvagno, Gian Luca, Henry, Brandon M., Pighi, Laura, de, Nitto Simone, Lippi, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Medical Biochemists of Serbia, Belgrade 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010038/
https://www.ncbi.nlm.nih.gov/pubmed/35510202
http://dx.doi.org/10.5937/jomb0-33999
_version_ 1784687397117624320
author Salvagno, Gian Luca
Henry, Brandon M.
Pighi, Laura
de, Nitto Simone
Lippi, Giuseppe
author_facet Salvagno, Gian Luca
Henry, Brandon M.
Pighi, Laura
de, Nitto Simone
Lippi, Giuseppe
author_sort Salvagno, Gian Luca
collection PubMed
description BACKGROUND: This study aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers after voluntary vaccination with Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA-based vaccine. METHODS: The study population consisted of 787 healthcare workers (mean age 44±12 years; 66% females), who received two 30 mg doses of Pfizer-BioNTech COVID-19 vaccine, 3 weeks apart. Venous blood was drawn before the first vaccine dose, immediately before the second vaccine dose, and then at 1, 3 and 6 months after the second vaccine dose. Serological testing employed the total antiSARS-CoV-2 antibodies measurement with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay. RESULTS: The median serum levels of total anti-SARS-CoV-2 antibodies reached the peak (1762 kU/L) 1 month after the second vaccine dose, but tended to progressively decline at the 3-month (1086 kU/L) and 6-month (802 kU/L) follow-up points. Overall, the values after 3and 6months were 37% and 57% lower than the corresponding concentrations measured at the peak. No healthcare worker had total anti-SARS-CoV-2 antibodies below the method-dependent cut-off after 6 months. The decline compared to the peak was more accentuated in baseline seropositive persons than in those who were baseline seronegative (74% vs. 52%) cohort. The 6-month post-vaccination anti-SARS-CoV-2 antibodies in subjects aged <65 years remained over 2-fold higher than in those aged ≥65 years (813 vs. 343 kU/L) and also remained consistently higher in women than in men. CONCLUSIONS: Gradual decline of total anti-SARS-CoV-2 antibodies occurred 6 months after Pfizer-BioNTech COVID-19 vaccination, though values remained higher than the method-dependent cut-off, with no case of sero-negativization.
format Online
Article
Text
id pubmed-9010038
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society of Medical Biochemists of Serbia, Belgrade
record_format MEDLINE/PubMed
spelling pubmed-90100382022-05-03 Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers Salvagno, Gian Luca Henry, Brandon M. Pighi, Laura de, Nitto Simone Lippi, Giuseppe J Med Biochem Original Paper BACKGROUND: This study aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers after voluntary vaccination with Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA-based vaccine. METHODS: The study population consisted of 787 healthcare workers (mean age 44±12 years; 66% females), who received two 30 mg doses of Pfizer-BioNTech COVID-19 vaccine, 3 weeks apart. Venous blood was drawn before the first vaccine dose, immediately before the second vaccine dose, and then at 1, 3 and 6 months after the second vaccine dose. Serological testing employed the total antiSARS-CoV-2 antibodies measurement with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay. RESULTS: The median serum levels of total anti-SARS-CoV-2 antibodies reached the peak (1762 kU/L) 1 month after the second vaccine dose, but tended to progressively decline at the 3-month (1086 kU/L) and 6-month (802 kU/L) follow-up points. Overall, the values after 3and 6months were 37% and 57% lower than the corresponding concentrations measured at the peak. No healthcare worker had total anti-SARS-CoV-2 antibodies below the method-dependent cut-off after 6 months. The decline compared to the peak was more accentuated in baseline seropositive persons than in those who were baseline seronegative (74% vs. 52%) cohort. The 6-month post-vaccination anti-SARS-CoV-2 antibodies in subjects aged <65 years remained over 2-fold higher than in those aged ≥65 years (813 vs. 343 kU/L) and also remained consistently higher in women than in men. CONCLUSIONS: Gradual decline of total anti-SARS-CoV-2 antibodies occurred 6 months after Pfizer-BioNTech COVID-19 vaccination, though values remained higher than the method-dependent cut-off, with no case of sero-negativization. Society of Medical Biochemists of Serbia, Belgrade 2022-04-08 2022-04-08 /pmc/articles/PMC9010038/ /pubmed/35510202 http://dx.doi.org/10.5937/jomb0-33999 Text en 2022 Gian Luca Salvagno, Brandon M. Henry, Laura Pighi, Nitto Simone de, Giuseppe Lippi, published by CEON/CEES https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License.
spellingShingle Original Paper
Salvagno, Gian Luca
Henry, Brandon M.
Pighi, Laura
de, Nitto Simone
Lippi, Giuseppe
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title_full Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title_fullStr Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title_full_unstemmed Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title_short Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers
title_sort total anti-sars-cov-2 antibodies measured 6 months after pfizer-biontech covid-19 vaccination in healthcare workers
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010038/
https://www.ncbi.nlm.nih.gov/pubmed/35510202
http://dx.doi.org/10.5937/jomb0-33999
work_keys_str_mv AT salvagnogianluca totalantisarscov2antibodiesmeasured6monthsafterpfizerbiontechcovid19vaccinationinhealthcareworkers
AT henrybrandonm totalantisarscov2antibodiesmeasured6monthsafterpfizerbiontechcovid19vaccinationinhealthcareworkers
AT pighilaura totalantisarscov2antibodiesmeasured6monthsafterpfizerbiontechcovid19vaccinationinhealthcareworkers
AT denittosimone totalantisarscov2antibodiesmeasured6monthsafterpfizerbiontechcovid19vaccinationinhealthcareworkers
AT lippigiuseppe totalantisarscov2antibodiesmeasured6monthsafterpfizerbiontechcovid19vaccinationinhealthcareworkers